US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Apnimed Inc. (APMD): Sleep-Related Biopharma in Phase 3 Sets Terms for IPO

Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Upsized IPO priced above expectations, with shares opening 37.5% above the IPO price despite significant early volatility.</li>
<li>Aggressive buying erased early losses, sending shares from near issue price to a 82% intraday gain.</li>
<li>Late-Stage clinical profile and favorable biotech sentiment continue supporting investor demand for quality healthcare IPOs.</li>
</ul>


Upsized IPO priced above expectations, with shares opening 37.5% above the IPO price despite significant early volatility.
Aggressive buying erased early losses, sending shares from near issue price to a 82% intraday gain.
Late-Stage clinical profile and favorable biotech sentiment continue supporting investor demand for quality healthcare IPOs.


Apnimed Inc. (APMD): Apnimed Awakens: Wild IPO Ride Ends with 56% First-Day Gain